A new study by RCSI University of Medicine and Health Sciences, based in Dublin, Ireland, and Sequence Bio, a genomics and precision medicine company based in St. John’s, Newfoundland and Labrador (NL), Canada, has produced the most detailed genetic analysis of people living in the Canadian province to date, demonstrating a unique founder population structure that could be used for the identification and study of health-related genetic variants.
By studying the genetic profiles of 1,807 volunteering individuals from Sequence Bio’s Newfoundland and Labrador Genome Project (NLGP), and comparing the resulting fine-scale genetic structure of NL to reference datasets for Ireland and England, scientists showed that a significant proportion of the European-derived population of NL can be traced back to settlers who primarily migrated from South-East Ireland and South-West England around three centuries ago.
“In looking at the ways Newfoundlanders and Labradorians are genetically related to each other, and to present day Irish and English individuals, we were able to show that European ancestry in NL is mainly descended from Irish and English settlers in the time of the late 1700s to early 1800s,” explains Dr Edmund Gilbert, a Lecturer at the School of Pharmacy and Biomolecular Sciences in RCSI and FutureNeuro, the Science Foundation Ireland (SFI) Research Centre for Chronic and Rare Neurological Diseases.
Dr Gilbert, the first author on the study, used well-characterised population reference datasets like the Irish DNA Atlas to link English and Irish ancestry in NL to specific regions in Ireland, and to track how social and geographical isolation influenced NL communities at the level of their DNA.
Dr Gerald Mugford, Director of Research at Sequence Bio commented on the study: “Through this expert collaboration with RCSI, we now have a much deeper understanding of the ancestry of the current NL population and the origins of genetic variants that could be meaningful for disease gene discovery in the province”.
Further analysis of the genetic data also shows multiple population bottlenecks, or reductions in population size, happening independently in the region around 300 years ago due to geographical isolation and tendency for people to settle with others from the same country of origin and religious affiliation.
Professor Gianpiero Cavalleri, Professor of Human Genetics at RCSI School of Pharmacy and Biomolecular Science and Deputy Director of the SFI FutureNeuro Research Centre, helped lead the comparative study of genomes from Canada, Ireland and England. He said, “The genetic analysis supports the historical accounts that around 25,000 European settlers came to NL in the 18th and 19th centuries, mainly from Ireland - predominantly Waterford, Wexford, south Kilkenny, southeast Tipperary, and southeast Cork - and from Dorset and Devon in England as well as fishing ports such as Dartmouth, Plymouth, or Southampton.
“In the study, we could see that Catholic background in Newfoundland and Labrador is still today strongly associated with Irish genetic ancestry as is Protestant background with English genetic ancestry.”
Dr. Michael Phillips, the study’s Senior Author commented: “Our findings support NL’s population structure as a unique genetic landscape with founder effects.” He also noted the potential clinical and health-related importance of these patterns. “Because NL resembles that of other isolated island populations, there may be an opportunity to study the genetic makeup of specific subpopulations in NL to identify rare genetic variants that contribute to the risk and severity of certain diseases.”
The study was produced in collaboration with researchers from the Genealogical Society of Ireland, Trinity College Dublin, the US National Human Genome Research Institute, and the Weatherall Institute of Molecular Medicine in Oxford.
Jane Butler, RCSI Communications Manager
firstname.lastname@example.org, +353 (0)87 7531877
Christopher McDonald, Sequence Bio Communications Manager
(800) 296-3481 x 708
RCSI University of Medicine and Health Sciences is a world-leading university for Good Health and Well-being. Ranked in the world top 50 for its contribution to UN Sustainable Development Goal 3 in the Times Higher Education Impact Rankings 2022, it is exclusively focused on education and research to drive improvements in human health worldwide.
RCSI is an international not-for-profit university, headquartered in Dublin. It is among the top 250 universities worldwide in the World University Rankings (2023). RCSI has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education.
Visit the RCSI MyHealth Expert Directory to find the details of our experts across a range of healthcare issues and concerns. Recognising their responsibility to share their knowledge and discoveries to empower people with information that leads them to better health, these clinicians and researchers are willing to engage with the media in their area of expertise.
Sequence Bio is a genomics and precision medicine company based in Newfoundland and Labrador, Canada. The company’s platform leverages Newfoundland’s founder effect to power discovery cohorts for novel target identification across numerous disease indications. Sequence Bio collaborates with the people of Newfoundland and Labrador, and partners with leading pharma and biotech, to help accelerate the development of new medicines for global unmet medical needs. For more information, please visit www.SequenceBio.com.
Sequence Bio would like to thank all volunteering participants who consented to participate in the NL Genome Project for enabling this research.
FutureNeuro is the SFI Centre Chronic and Rare Neurological Diseases led by RCSI Professor David Henshall (Director) and RCSI Professor Gianpiero Cavalleri (Deputy Director) www.futureneurocentre.ie. In partnership with the national clinical network for neurology, the centre contributes to improving the health and health-care of people with neurological disease. FutureNeuro’s unique approach is to explore multiple related aspects of brain disease across the themes of diagnostics, therapeutics and eHealth.
VP, Market Development